CTOR
$0.77
Citius Oncology, Inc.
Recent News
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following the December 2025 commercial launch of LYMPHIR. For FQ1 2026, the company reported $3.9 million in consolidated revenue, reflecting initial sales through a nationwide network of specialty distributors. […]
Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar
Citius Oncology Inc. (NASDAQ:CTOR) is one of the most undervalued penny stocks to buy right now. On February 11, Citius Oncology entered into an exclusive distribution agreement with Uniphar to expand the availability of its oncology treatment, LYMPHIR, throughout Western and Eastern Europe. This partnership marked Citius Oncology’s third major international agreement, following similar arrangements […]
Citius Oncology and Uniphar sign European distribution deal for Lymphir
Uniphar will act as the exclusive distributor for Lymphir in designated European territories.
When Will Citius Oncology, Inc. (NASDAQ:CTOR) Become Profitable?
With the business potentially at an important milestone, we thought we'd take a closer look at Citius Oncology, Inc.'s...
How Investors Are Reacting To McKesson (MCK) Securing LYMPHIR’s Distribution Ahead of U.S. Launch
In October 2025, Citius Oncology announced a distribution services agreement with McKesson, making McKesson an authorized distributor of record for LYMPHIR, a newly FDA-approved immunotherapy for certain cutaneous T-cell lymphoma patients, with national distribution ahead of its planned commercial launch later in the year. This collaboration completes LYMPHIR’s U.S. distribution network through the nation’s three largest pharmaceutical wholesalers, highlighting McKesson’s central role in...